Orencia Extension Data Show Two-Year Progression Benefits In RA Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb says abatacept sustains inhibition of radiographic progression over two years in methotrexate-inadequate responders.